Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy.

Brouwers AH, Mulders PF, Oyen WJ.

J Clin Oncol. 2008 Aug 1;26(22):3808-9; author reply 3811-2. doi: 10.1200/JCO.2008.17.6073. No abstract available.

PMID:
18669472
2.

Carbonic anhydrase IX expression in clear cell renal cell carcinomas negatively correlates with the proportion of the granular cell component.

Skapa P, Hyrsl L, Zavada J, Soukup J, Zamecnik J.

J Clin Oncol. 2008 Aug 1;26(22):3809-11; author reply 3811-2. doi: 10.1200/JCO.2008.17.6511. No abstract available.

PMID:
18669473
3.

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratama JW, Stoter G, Oosterwijk E.

J Clin Oncol. 2006 May 1;24(13):e20-2. No abstract available.

PMID:
16648493
4.

Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.

Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E.

Eur Urol. 2010 Jul;58(1):75-83. doi: 10.1016/j.eururo.2010.03.015. Epub 2010 Mar 23. Review.

PMID:
20359812
5.

Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray.

Zerati M, Leite KR, Pontes-Junior J, Segre CC, Reis ST, Srougi M, Dall'Oglio MF.

Int Braz J Urol. 2013 Jul-Aug;39(4):484-92. doi: 10.1590/S1677-5538.IBJU.2013.04.05.

6.

In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer.

Brouwers AH, Boerman OC, Oyen WJ.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8886; author reply 8886. No abstract available.

7.

Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies.

Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, Russo P, Motzer RJ, Reuter VE, Tickoo SK.

Am J Surg Pathol. 2008 Mar;32(3):377-82. doi: 10.1097/PAS.0b013e3181570343.

PMID:
18300814
8.

Carbonic anhydrase IX as a predictive biomarker for clear cell renal cell carcinoma.

Pantuck AJ, Klatte T, Seligson D, Atkins M, Belldegrun A.

J Clin Oncol. 2008 Jun 20;26(18):3105-7; author reply 3107-9. doi: 10.1200/JCO.2008.16.1935. No abstract available.

PMID:
18565906
9.

Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.

Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF.

Eur Urol. 2013 Sep;64(3):478-85. doi: 10.1016/j.eururo.2012.08.024. Epub 2012 Aug 21.

PMID:
22980441
10.
11.

Carbonic anhydrase IX: historical and future perspectives.

Oosterwijk E.

BJU Int. 2008 Jun;101 Suppl 4:2-7. doi: 10.1111/j.1464-410X.2008.07641.x. Review. No abstract available.

12.

Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma.

Jensen HK, Nordsmark M, Donskov F, Marcussen N, von der Maase H.

BJU Int. 2008 Jun;101 Suppl 4:41-4. doi: 10.1111/j.1464-410X.2008.07649.x. No abstract available.

13.

Carbonic anhydrase IX/G250/MN: a molecule too good to be true?

Oosterwijk E.

BJU Int. 2008 Mar;101(5):527-8. doi: 10.1111/j.1464-410X.2007.07431.x. No abstract available.

14.

Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.

Donato DP, Johnson MT, Yang XJ, Zynger DL.

Histopathology. 2011 Dec;59(6):1229-39. doi: 10.1111/j.1365-2559.2011.04074.x.

PMID:
22175902
15.

Carbonic anhydrase IX and renal cell carcinoma: prognosis, response to systemic therapy, and future vaccine strategies.

Shuch B, Li Z, Belldegrun AS.

BJU Int. 2008 Jun;101 Suppl 4:25-30. doi: 10.1111/j.1464-410X.2008.07645.x. Review. No abstract available.

16.

The use of positron-emission tomography in the diagnosis of tumour phenotype.

Divgi C.

BJU Int. 2008 Jun;101 Suppl 4:36-8. doi: 10.1111/j.1464-410X.2008.07647.x. Review. No abstract available.

17.

Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma.

Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF.

Eur Urol. 2013 Jun;63(6):1101-6. doi: 10.1016/j.eururo.2013.02.022. Epub 2013 Feb 21.

PMID:
23453421
18.

Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma.

Leppert JT, Lam JS, Pantuck AJ, Figlin RA, Belldegrun AS.

BJU Int. 2005 Aug;96(3):281-5.

19.

Deal watch: Phase III antibody targeting tumour pH acquired in Prometheus deal.

[No authors listed]

Nat Rev Drug Discov. 2011 Jul 1;10(7):482. doi: 10.1038/nrd3496. No abstract available.

PMID:
21720396
20.

A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.

Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM.

Cancer Immun. 2007 Aug 17;7:13.

Supplemental Content

Support Center